% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 Aug 23, 2013 10:34 AM Flag

    New study with MEK 162 by Novartis just started

    Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • dcaf, first off want to say thanks for all the informational posts.I am long ARRY. I was wondering what your longterm PPS projections would be for ARRY would be, looking ot 9-14 months
      Thank you in advance

      • 1 Reply to tuna_20_25
      • It is very difficult to predict. I think it will be higher, but how much higher, I don't know. It depends on:
        1. The results from their MM and MDS trials to be presented at ASH 2013 in December.
        2. When they can initiate pivotal trials with 520 and 614 and the design of studies.
        3. The results of phase 3 NEMO study by Novartis, which could be known in October 2014.
        4. Partnering asthma and pain drugs and terms of agreements.
        5. Progress in Selumetinib programs.
        6. Decision about Danoprevir. Advancement into Phase 3 by Roche would be huge catalyst for ARRY.
        7. Dilutions.
        8. Overall market conditions.
        Welcome to add more factors.

6.42-0.16(-2.43%)Oct 21 4:00 PMEDT